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Abstract
Background: The role of biologic therapies in the treatment of rheumatoid arthritis has expanded, but dosing
patterns in the first versus subsequent lines of therapy have not been thoroughly explored.
Methods: In order to describe patterns of biologic agent utilization among patients with rheumatoid arthritis,
health care claims data on use of abatacept, rituximab, or the anti-tumor necrosis factor (TNF) agents etanercept,
adalimumab, and infliximab in first- or subsequent-line settings were used to form patient cohorts. Variables
included: starting dose (first administration or fill), maintenance dose (third administration or fill), average dose,
dose escalation, inter-infusion interval, and discontinuation (gap in therapy > 60 days or switch). Time to
discontinuation was assessed with Kaplan-Meier curves and Cox proportional hazards models.
Results: Over 1 year, average (SD) doses of first-line etanercept (N = 1593; 45.4 [8.8] mg/week), adalimumab (N =
1040; 40.7 [10.4] mg/2 weeks), and abatacept (N = 360; 715.4 [214.5] mg/4 weeks) were similar to the starting and
maintenance doses; the average infliximab dose (N = 538; 441.0 [209.2] mg/8 weeks) was greater than the starting
and maintenance doses. Trends in the subsequent-line anti-TNF cohorts were similar. The percentages with a dose
escalation or discontinuation were greater in the subsequent-line anti-TNF cohorts. The proportion with a dose
escalation was greatest for the infliximab cohorts (61.2% first-line and 80.2% subsequent-line). The average period
between abatacept infusions was 4.8 [1.4] weeks (4-week approved schedule); and 6.8 [2.6] months between
rituximab courses (currently approved schedule is 6 months). Time to discontinuation was significantly shorter for
subsequent-line than first-line anti-TNF therapy (median 9.7 vs. 12.5 mo; p < 0.001). The hazard ratio for
discontinuing subsequent-line versus first-line anti-TNF therapy was 1.177 (p < 0.001).
Conclusions: Subsequent-line anti-TNF therapy cohorts had higher rates of discontinuation, dose escalation, and
shorter time to discontinuation than first-line anti-TNF cohorts.
Background
Rheumatoid arthritis (RA) is a systemic autoimmune
disease characterized by joint inflammation and progres-
sive damage, as well as cardiac, pulmonary, ocular, and
neurological complications [1,2]. These disease features
are associated with increased disability and mortality
[1,3]. The primary goal of RA treatment is remission or
low disease activity [4,5], and therapies targeted to mini-
mizing disease activity lead to achievement of other
treatment goals, including pain control and prevention
of joint damage and loss of function [4-8]. Current
treatment strategies include long-term use of traditional
and biologic disease-modifying anti-rheumatic drugs
(DMARDs), as well as non-steroidal anti-inflammatory
drugs (NSAIDs) and glucocorticoids.
Use of biologic DMARDs has increased over the past
15 years [9-11] and current recommendations advocate
early use of biologic agents following an insufficient
response to initial non-biologic DMARD therapy
[4,12,13]. Several biologic DMARDs are available, and
they differ in mechanism of action, route of administra-
tion, and frequency of administration. As of early 2009
(the end of the period investigated in this study),
approved biologic DMARDs included the tumor
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any medium, provided the original work is properly cited.necrosis factor (TNF) inhibitors etanercept, adalimumab,
and infliximab, as well as a CD-20+ B-cell directed ther-
apy, rituximab, and a selective T-cell costimulation
modulator, abatacept. Etanercept and adalimumab are
both self-administered as subcutaneous injections,
whereas infliximab, rituximab, and abatacept are admi-
nistered by intravenous infusion. Dosing intervals range
from every week (etanercept) to a 2-dose course every 6
months (rituximab). These differentiating characteristics,
as well as patient preferences together with clinical con-
siderations are likely to affect the suitability of any of
these medications for individual patients and thus ther-
apy utilization patterns in real-world settings.
Studies have described patterns of biologic therapy uti-
lization in RA, including characteristics of patients who
receive biologics and what agents they receive [10,14],
but dosing patterns in the first versus subsequent lines of
therapy have not been thoroughly explored. With a goal
of further understanding the use of biologic therapies in
RA treatment, objectives of this study were to describe
patterns of biologic utilization among commercially
insured patients with RA, to compare utilization patterns
of anti-TNF agents used as a first versus as a subsequent
biologic agent, and to compare real-world dosing pat-
terns with label recommendations.
Methods
Patient sample and data source
Commercially insured patients with evidence of RA
were retrospectively identified in a large healthcare
claims database affiliated with Innovus (now OptumIn-
sight). The database includes enrollment information
and medical and pharmacy claims from geographically
diverse commercial health plan enrollees in the United
States. To be eligible, patients were required to have at
least 1 claim for a biologic agent of interest during the
identification period 01 Feb 2006 through 31 Jan 2008.
These agents were: adalimumab, etanercept, abatacept,
infliximab, and rituximab. These medications represent
the biologic agents approved for treatment of RA in the
US during the study period, excluding the less fre-
quently used biologic agent, anakinra. Biologic agents
approved after the end of our study period (i.e., tocilizu-
mab, cetrolizumab, and golimumab) were not included
in this study. The self-injectable drugs adalimumab and
etanercept were identified based on pharmacy claims,
and the infused medications abatacept, infliximab, and
rituximab were identified using medical (i.e., facility and
physician) claims. Specifically, Healthcare Common Pro-
cedure Coding System (HCPCS) codes C9230, J0129,
and J3590 were used to identify abatacept use, J1745
and S9359 were used to identify infliximab use, and
J9310 was used to identify rituximab use. The date of
the first use for any of these medications during the
identification period was defined as the index date. If a
patient had evidence of use of more than one of the
medications of interest during the identification period,
that patient could have multiple index dates and be
included in more than one cohort, as described in the
“Patient cohorts” section.
Patients were required to be continuously enrolled for
6 months prior to the index date (baseline period) and
at least 12 months following the index date. The follow-
up period extended from the index date until disconti-
nuation or 1 year, whichever occurred earlier. At least
one medical claim during the baseline period with RA
diagnosis (ICD-9-CM 714.xx) in any position was
required, and patients must have been aged at least 18
years as of the index date.
Patients were excluded if there was evidence of more
than one biologic agent on the index date, evidence of
receipt of the index medication prior to the index date,
or diagnosis, at any time during the study period, of
another indication for which the study biologics could
be prescribed (Additional File 1, Table S1). Patients with
> 50% more infusions or prescription fills per year than
currently recommended in label guidelines for RA were
excluded. Patients with pharmacy claims for adalimu-
mab or etanercept indicating zero days supply or unu-
sually high average daily dose (e.g., more than 40 mg/
day for adalimumab or more than 30 mg/day for etaner-
cept); or patients who had medical claims during follow-
up for these normally self-administered medications,
were excluded. Patients with medical claims for inflixi-
mab, abatacept, or rituximab that were missing units,
and patients with pharmacy claims for these infused
drugs during follow-up were excluded.
No identifiable protected health information was
extracted or accessed during the course of the study.
Pursuant to the Health Insurance Portability and
Accountability Act [15], the use of de-identified data
does not require institutional review board approval or
waiver of authorization.
Patient cohorts
Patients could be included in more than one cohort
depending on their use of the biologic agents of interest.
Cohort assignment was based on a hierarchical identifi-
cation of the index medication. First, patients with med-
ical claims for rituximab during the identification period
were identified and the first administration date defined
as the index date for rituximab. Second, patients with
medical claims for abatacept were identified and the
first use date defined as the index date for abatacept.
Patients could be included in both the rituximab and
abatacept cohorts. Third, patients with claims for anti-
TNF agents (etanercept, adalimumab, infliximab) were
identified. Patients whose first anti-TNF use occurred
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anti-TNF cohorts.
Patients with an index anti-TNF were classified into
first-line or subsequent-line anti-TNF cohorts based
on evidence of anti-TNF use in the pre-index period.
Patients with an index anti-TNF agent and no evidence
of biologic use for RA prior to the index date (not
restricted to the baseline period) were assigned to the
first-line anti-TNF cohort. Patients with an index anti-
TNF agent and a different anti-TNF agent in the pre-
index period or who were previously in a different
anti-TNF first-line cohort comprised the subsequent-
line anti-TNF cohorts. The terms “first-line” and “sub-
sequent-line” in this report refer specifically to anti-
TNF use and do not reflect the use of other therapy
for RA prior to initiating treatment with a biologic
agent. Because rituximab and abatacept are most fre-
quently used by patients who had an inadequate
response to at least one anti-TNF, the rituximab and
abatacept cohorts were not separated by “line” of bio-
logic therapy.
Study measures
The 6-month period prior to the index date was used to
assess patient characteristics including comorbidities
and prior use of therapy for RA. The burden of comor-
bidities was quantified using the Charlson comorbidity
index [16]. Variables assessed in the post-index follow-
up period included dose, dose escalation, discontinua-
tion, and switching. These various descriptors were used
to characterize actual doses used and changes over the
course of treatment.
Biologic agent doses
Dosing was measured differently for infused and
injected therapies. For infused therapies, the dose is
recorded on the medical claim as the number of units
billed for; these units were converted to milligrams. For
injected therapies, an average daily dose was calculated
based on the strength, quantity dispensed, and days’
supply for specified fills (strength×quantity dispensed/
days supply).
Biologic agent doses: starting dose
Starting and maintenance doses were determined for the
anti-TNF and abatacept cohorts. “Starting” dose was
defined as the recorded dose of the first administration
for the infused anti-TNF products infliximab or abata-
cept, and as the average daily dose for the first fill of
self-injected etanercept and adalimumab.
Biologic agent doses: maintenance dose
“Maintenance” dose was defined as the recorded dose of
the third administration (infliximab and abatacept) or
average daily dose for the third prescription fill (etaner-
cept and adalimumab) among patients who had at least
3 infusions/fills before discontinuation.
Biologic agent doses: average dose
For anti-TNF cohorts with index medications dosed at
regular intervals (etanercept, adalimumab), the average
daily dose was calculated from the index date through
follow-up (discontinuation or 1 year) among all patients
in the cohort. For abatacept and infliximab cohorts,
which have an initial loading period, an average daily
dose was calculated based on all administrations from
the third dose onward (post-loading period) among
patients with at least 3 infusions during the follow-up
period. The number of milligrams infused over the post-
loading period was divided by the number of days from
the third dose through the remainder of follow-up and
this average daily dose was converted to dose per the
recommended inter-infusion interval.
Biologic agent doses: last dose
The “last” dose, or the dose preceding discontinuation,
switch, or at the end of the follow-up period was cap-
tured. The last dose was defined as the recorded dose of
the last administration (infliximab and abatacept) or
average daily dose for the last prescription fill (etaner-
cept and adalimumab).
Anti-TNF agent dose escalation
Dose escalation was defined as a reduced interval
between anti-TNF infusions or an increased average
daily dose of an anti-TNF agent [17]. Patients using
injected anti-TNF agents had a dose escalation if the
average daily dose calculated for 2 or more consecutive
prescription fills was greater than the maintenance dose.
To avoid labeling the initial loading dose as an escala-
tion, dose escalation for the infliximab cohort was
defined as 2 reported doses greater than the mainte-
nance dose, or 2 infusions within 7 weeks on 2 or more
occasions. Escalation was assessed for patients in the
anti-TNF cohorts who had at least 5 fills or infusions.
Infusion intervals
For patients in all infused therapy cohorts (infliximab,
rituximab, abatacept), dosing was described based on
the number of infusions and the time between infusions.
The number of infusions was tabulated from follow-up
period medical claims with evidence of index agent
administration. The number of days between infusions
was determined in order to compare timing with label
guidelines [18-20]. For infliximab and abatacept cohorts,
the loading period (time to complete the first three infu-
sions) and infusion intervals during the post-loading
period (from the third infusion onward) were assessed
separately. The time between infusions was calculated
from among patients with more than one infusion.
Rituximab is administered in 2-dose courses and the
number of days between doses and between courses was
calculated. A course was defined as receipt of a second
infusion within 30 days. The number of days between
courses was determined among patients with more than
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infusion of the first course and the first infusion of the
second course.
Discontinuation of the index biologic agent
The proportion of patients discontinuing therapy and
the time to discontinuation were determined for the
anti-TNF and abatacept cohorts. “Discontinuation” was
defined as a prolonged gap in supply of the index medi-
cation or when a patient had evidence of starting a non-
index biologic medication during the follow-up period.
The allowed gap in supply was initially defined as up to
60 days, and a sensitivity analysis allowing a gap of up
to 180 days was also conducted. Patients with supply
gaps longer than these allowed periods or who had evi-
dence of non-index biologic agent use during the fol-
low-up year were considered to have discontinued index
therapy. For etanercept and adalimumab, the disconti-
nuation date was defined as the last prescription fill date
plus the days supply of that fill. For the infused thera-
pies infliximab and abatacept, the discontinuation date
was defined as the last infusion date plus the recom-
mended interval before the next administration, specifi-
cally, 8 weeks for infliximab and 4 weeks for abatacept
[18,19]. If a patient had evidence of starting a non-index
biologic medication during the follow-up period, the dis-
continuation date of the index therapy was the date of
the first fill or infusion of the new medication. The
rituximab cohort was not included in the analyses of
discontinuation because a retreatment interval was not
specified on the product label during the study period.
The rituximab label currently recommends a 6 month
interval between courses.
Switching of biologic agents
The proportion of patients in each cohort who switched
biologic therapy, i.e., had evidence of non-index biologic
therapy use during the follow-up year was determined.
The assessment period for switching covered the year
following the index date, regardless of gaps in supply of
the index therapy.
Statistical analysis
Patient characteristics were analyzed descriptively by
cohort. Means and standard deviations are provided for
continuous variables and numbers and percentages are
provided for dichotomous and polychotomous variables.
Kaplan-Meier survival plots were used to describe the
time-to-discontinuation and a Cox proportional hazards
model was constructed to compare time-to-discontinua-
tion between anti-TNF agents used in the first- versus
subsequent-line settings while controlling for demo-
graphic (age, sex, region, insurance type) and clinical
characteristics (Charlson comorbidity index, baseline
methotrexate, NSAID, or corticosteroid use). Time-to-
discontinuation was calculated based on the index date
and discontinuation date without limiting the follow-up
to 1 year. We used p < 0.05 to define statistical signifi-
cance in the analysis of time to discontinuation. The
Kaplan-Meier curves and Cox proportional hazard
model were fit by STATA 10.0 (StataCorp, College Sta-
tion, Texas) and all other analyses were conducted using
SAS 9.1 (SAS, Cary, North Carolina).
Results
Cohort characteristics
Demographic and clinical characteristics of the patient
cohorts are shown in Table 1. Across all cohorts, 59.3%
to 67.7% of patients were aged 45 to 64 years. The
source database population is comprised heavily of
patients in the South region, and, as shown in Table 1,
the geographic distribution of the database is reflected
among patients with RA who were included in the
study. Comorbidity scores were similar across the anti-
TNF cohorts and were slightly higher among patients
receiving abatacept or rituximab, suggesting greater
comorbidity burden. In the baseline period, more than
half of patients in every cohort used corticosteroids or
methotrexate, and NSAID use was also common (Table
1). Median follow-up times ranged from 555 days (ritux-
imab) to 661 days (subsequent-line adalimumab), indi-
cating that at least half of patients in every cohort had
at least 18 months of follow-up.
Biologic agent doses
The doses received by patients with anti-TNF and aba-
tacept biologic therapy are described in Table 2. For the
self-injected therapies etanercept and adalimumab, the
mean starting dose and maintenance dose were similar
to the approved label dose for both first-line and subse-
quent-line cohorts. Appropriate infliximab and abatacept
dosing is dependent on patient weight, which was not
available in the dataset, but the mean starting and main-
tenance doses are presented in Table 2 for comparison.
The average doses calculated for etanercept, adalimu-
mab, and abatacept for the specified intervals are similar
to the starting and maintenance doses, whereas the
average infliximab dose per 8 weeks (the recommended
infusion interval), was greater than the starting or main-
tenance doses, especially among patients who received
infliximab after failure of a previous anti-TNF agent
(Table 2).
Anti-TNF agent dose escalation
The proportion of patients with a dose escalation was
greater for the infliximab cohorts (61.2% for first-line
and 80.2% for subsequent use) than for the other anti-
TNF groups (Table 2). For all therapies, the percentage
with dose escalation was greater for the subsequent-line
biologic cohorts than the first-line cohorts, with that
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imab (Table 2).
Infusion intervals
Among patients who had infused biologic therapy, the
number and timing of administrations provides addi-
tional information about treatment patterns. Over the
follow-up period, a mean (± SD) of 7 ± 3 infusions was
observed per patient among those in either the first- or
subsequent-line infliximab cohorts, 3 ± 1 infusions were
captured for the rituximab cohort and 10 ± 4 infusions
were noted for the abatacept cohort. According to their
prescribing information, the first 3 doses of infliximab
and abatacept should be administered within a shorter
time frame than later maintenance doses. For infliximab,
these loading doses are sch e d u l e df o r2a n d6w e e k s
after the initial infusion. For patients with infliximab as
a first-line biologic and at least 3 infusions (n = 538),
42.2% completed the 3 loading doses within 6 weeks
after the initial infusion and a total of 78.1% completed
the 3-dose series within 8 weeks. The proportion of
patients who received the loading doses in the recom-
mended period was higher for patients receiving inflixi-
mab as a subsequent-line biologic; among those with at
least 3 infusions (n = 144), 47.2% completed the loading
doses within 6 weeks after the initial infusion and a
total of 88.2% had all 3 doses within 8 weeks.
Following the loading period, infliximab is indicated
for infusion every 8 weeks as per the label. The aver-
age time between infusions in the post-loading period
in our study is shown in Table 3. The mean dosing
interval was shorter for patients with infliximab as a
subsequent-line biologic than for those who used it
first-line and in both settings the average interval was
shorter than the label recommendation. As shown in
Figure 1, the most frequently observed average dosing
interval for both the first- and subsequent-line inflixi-
mab cohorts aligned with the recommended 8 weeks
(37.2% and 30.9%, respectively), although 50.4% (first
line) and 61.8% (subsequent line) of individuals had a
shorter than recommended average period between
infusions.
The abatacept loading period should be completed
within 4 weeks of the initial infusion. For patients in
the abatacept cohort who had at least 3 infusions (n =
360), 39.2% completed these loading doses within 4
weeks. Another 31.9% completed the 3-dose loading
series between 4 and 6 weeks after the initial infusion.
Table 1 Baseline patient characteristics
First anti-TNF Subsequent anti-TNF
Etanercept
(N = 1593)
Adalimumab
(N = 1040)
Infliximab
(N = 584)
Etanercept
(N = 258)
Adalimumab
(N = 353)
Infliximab
(N = 156)
Abatacept
(N = 418)
Rituximab
(N = 239)
Age; mean (SD) 49.9 (12.4) 50.1 (12.0) 52.8 (11.4) 50.0 (10.9) 49.9 (11.2) 49.1 (11.6) 52.8 (11.8) 52.7 (11.3)
Male; n (%) 346 (21.7) 245 (23.6) 145 (24.8) 56 (21.7) 64 (18.1) 31 (19.9) 69 (16.5) 48 (20.1)
Quan-Charlson score;
mean (SD)
1.3 (0.8) 1.3 (0.9) 1.4 (0.9) 1.4 (0.8) 1.4 (0.9) 1.3 (0.8) 1.5 (1.0) 1.7 (1.1)
Medications; n (%)
Oral and injectable
corticosteroids
946 (59.4) 665 (63.9) 413 (70.7) 189 (73.3) 249 (70.5) 109 (69.9) 313 (74.9) 177 (74.1)
Methotrexate 833 (52.3) 606 (58.3) 401 (68.7) 142 (55.0) 177 (50.1) 89 (57.1) 213 (51.0) 120 (50.2)
NSAIDs 739 (46.4) 522 (50.2) 291 (49.8) 126 (48.8) 188 (53.3) 75 (48.1) 209 (50.0) 104 (43.5)
Antimalarials 274 (17.2) 192 (18.5) 104 (17.8) 41 (15.9) 65 (18.4) 23 (14.7) 41 (9.8) 26 (10.9)
Other DMARDs
a 263 (16.5) 169 (16.3) 93 (15.9) 49 (19.0) 57 (16.1) 21 (13.5) 78 (18.7) 42 (17.6)
Immunosuppressants 22 (1.4) 14 (1.3) 3 (0.5) 2 (0.8) 7 (2.0) 6 (3.8) 22 (5.3) 7 (2.9)
Gold salt 1 (0.1) 1 (0.1) 0 (0) 1 (0.4) 1 (0.3) 1 (0.6) 2 (0.5) 1 (0.4)
Biologics; n (%)
Etanercept 0 (0) 0 (0) 0 (0) 0 (0) 276 (78.2) 81 (51.9) 71 (17.0) 38 (15.9)
Adalimumab 0 (0) 0 (0) 0 (0) 166 (64.3) 0 (0) 62 (39.7) 60 (14.4) 42 (17.6)
Infliximab 0 (0) 0 (0) 0 (0) 57 (22.1) 55 (15.6) 0 (0) 141 (33.7) 54 (22.6)
Abatacept 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1
b (0.6) 0 (0) 31 (13.0)
Rituximab 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 11 (2.6) 0 (0)
Follow-up (days); mean
(SD)
656.9 (219.1) 664.1 (215.8) 685.4 (210.2) 677.9 (191.1) 691.1 (207.9) 675.2 (216.0) 636.4 (190.2) 617.0 (178.9)
acyclophosphamide, d-penicillamine, leflunomide, sulfasalazine.
bJ3590 (unclassified biologics) was included among the codes used to identify abatacept use; one patient had a claim with J3590 prior to the abatacept approval
date and it was assumed that the code was used to refer to biologic use unrelated to rheumatoid arthritis.
DMARD, disease-modifying antirheumatic drug; EPO, exclusive provider organization; HMO, health maintenance organization; NSAID, non-steroidal anti-
inflammatory drug; POS, point-of-service; PPO, preferred provider organization.
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ing interval was longer than the label indication (Table
3), but most patients’ (73.8%) mean infusion interval
aligned with the recommended 4-week duration (Fig-
ure 1).
Rituximab is administered in 2-dose courses, with the
doses separated by 2 weeks and courses separated by 6
months. Among patients who had at least 2 rituximab
infusions administered as a course (n = 200), the mean
number of days between the infusions was 15.7 ± 3.0.
Figure 1 shows that, among patients who had at least 2
courses (n = 139), 23% had an average between-course
interval of 6 to 7 months (24 to 27 full weeks), 21% had
an average interval of less than 6 months, and 56% had
an average interval of more than 7 months.
Discontinuation
When “discontinuation” was defined as a gap of more
than 60 days or starting a non-index biologic agent, the
proportion of patients that discontinued each subse-
quent-line anti-TNF therapy was greater than the pro-
portion that discontinued the respective first-line anti-
TNF treatment during the 1-year follow-up period
(Table 4). The proportion of patients discontinuing anti-
TNF treatment was highest for adalimumab in both set-
tings. The proportion of patients receiving abatacept
who discontinued was within the range of subsequent-
line anti-TNFs. When the gap used to define disconti-
nuation was extended to more than 180 days, the overall
proportion discontinuing decreased, but the relative pat-
tern remained the same (Table 4). The proportion
Table 2 Dosing of anti-TNFs as first or subsequent line biologic therapy and abatacept
First anti-TNF Subsequent anti-TNF
Etanercept
(N = 1593)
Adalimumab
(N = 1040)
Infliximab
(N = 584)
Etanercept
(N = 258)
Adalimumab
(N = 353)
Infliximab
(N = 156)
Abatacept
(N = 398)
Label dose
[18,19,40,41]
50 mg/week 40 mg/2 weeks 3 mg/kg
a/
infusion
50 mg/week 40 mg/2 weeks 3 mg/kg
a/
infusion
500-1000 mg
b/
infusion
Starting dose
c mean ± SD 48.8 ± 18.3
mg/week
43.0 ± 19.7
mg/2 weeks
313.9 ± 98.7
mg/infusion
49.4 ± 17.6
mg/week
43.2 ± 13.8
mg/2 weeks
311.8 ± 101.7
mg/infusion
756.8 ± 350.1
mg/infusion
Maintenance
dose
d
Eligible (n) 1229 799 528 191 248 143 347
mean ± SD 48.9 ± 13.1
mg/week
42.1 ± 10.4
mg/2 weeks
328.6 ± 109.0
mg/infusion
48.0 ± 6.6
mg/week
45.0 ± 13.7
mg/2 weeks
340.6 ± 107.6
mg/infusion
732.7 ± 221.0
mg/infusion
Average
dose
e
Eligible (n) 1593 1040 538
f 258 353 144
f 360
f
mean ± SD 45.4 ± 8.8
mg/week
40.7 ± 10.4
mg/2 weeks
441.0 ± 209.2
mg/8 weeks
47.8 ± 19.0
mg/week
45.4 ± 14.9
mg/2 weeks
556.2 ± 694.1
mg/8 weeks
715.4 ± 214.5
mg/4 weeks
Dose
escalation
Eligible
g (n) 112 139 279 25 48 97 –
Percentage
of patients
11.1% 21.7% 61.2% 15.9% 24.1% 80.2% –
aPatient weight.
bRecommended doses are 500 mg for patients < 60 kg, 750 mg for patients 60 to 100 kg, 1000 mg for patients > 100 kg.
cStarting doses for etanercept and adalimumab defined as the average daily dose of the first fill, which was converted to milligrams per the label treatment
interval by multiplying by the appropriate number of days. The starting infliximab and abatacept infusion doses are reported as milligrams administered.
dMaintenance dose defined as the recorded dose of the third administration (infliximab and abatacept) or average daily dose (converted to milligrams per the
recommended treatment interval) for the third prescription fill (etanercept and adalimumab) among patients who had at least 3 infusions/fills before
discontinuation (> 90 day gap).
eAverage daily dose calculated over the 1-year follow-up period (etanercept, adalimumab) or for the post-loading period (infliximab, abatacept) and converted to
the label treatment interval by multiplying by the appropriate number of days.
fRequires at least 3 infusions.
gRequires at least 5 prescriptions fills or infusions.
hLast dose defined as the recorded dose of the last administration (infliximab and abatacept) or average daily dose (converted to milligrams per the
recommended treatment interval) for the last prescription fill (etanercept and adalimumab).
Table 3 Recommended and observed time between infusions for intravenous biologics
First-line infliximab
a
(n = 506)
Subsequent-line infliximab
a
(n = 136)
Abatacept
a
(n = 344)
Rituximab
b
(n = 139)
Label interval 8 weeks 8 weeks 4 weeks 6 months
Observed interval; mean (SD) 7.82 (2.19) weeks 7.39 (2.09) weeks 4.75 (1.42) weeks 6.8 (2.6) months
aInterval between doses starting with dose 3, among patients with at least 4 infusions in the follow-up period.
bInterval defined as the number of days between dose 1 of first course and dose 1 of subsequent course.
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Page 6 of 11discontinuing from subsequent-line anti-TNF therapy
was still higher than from first-line therapy, and the ada-
limumab cohorts still had the highest proportion discon-
tinuing among the anti-TNF cohorts (42.6% for first-line
and 56.4% for subsequent-line).
The Kaplan-Meier curves depicting time to disconti-
nuation for first and subsequent-line anti-TNF therapy
are shown in Figure 2. When assessed with a 60 day gap
allowance (Figure 2a), time to discontinuation was sig-
nificantly shorter for subsequent-line anti-TNF therapy
than first-line anti-TNF therapy (p < 0.001). The median
time to discontinuation of first and subsequent-line anti-
TNF therapy, respectively, was 15.3 and 13.1 months for
infliximab (p = 0.164), 12.3 and 9.7 months for etaner-
cept (p = 0.103), and 10.9 months and 7.3 months for
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Figure 1 Time between infusions. The percentages of patients
with the indicated mean infusion intervals during the post-loading
period are shown among those with at least 4 infusions in the
infliximab cohorts (first line infliximab n = 506; subsequent line
infliximab n = 136) and the abatacept cohort (n = 344), and the
percentage of patients with the indicated mean time between
infusion courses among those with at least 2 courses is shown for
the rituximab cohort (n = 139). Dashed lines indicate the current
product label intervals (the course interval for rituximab was added
to the label after the study period).
Table 4 Percentage of patients discontinuing anti-TNF first- or subsequent-line biologic therapy and abatacept
First anti-TNF Subsequent anti-TNF
Discontinuation definition Etanercept
(N = 1593)
Adalimumab
(N = 1040)
Infliximab
(N = 584)
Etanercept
(N = 258)
Adalimumab
(N = 353)
Infliximab
(N = 156)
Abatacept
(N = 398)
60 day gap or non-index biologic start 49.9% 52.9% 39.6% 52.7% 63.7% 45.5% 53.1%
180 day gap or non-index biologic start 36.7% 42.6% 33.4% 43.8% 56.4% 41.7% 18.0%
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Figure 2 Time to discontinuation of first and subsequent anti-
TNF therapy. When discontinuation was defined as: (a) a gap in
therapy of more than 60 days or starting a non-index biologic
agent, the median time to discontinuation was 12.5 months for
first-line therapy and 9.7 months for subsequent-line therapy (p <
0.001); or (b) a gap in therapy of more than 180 days or starting a
non-index biologic agent, the median time to discontinuation was
15.6 months for first-line therapy and 12.3 months for subsequent-
line therapy (p < 0.001).
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Page 7 of 11adalimumab (p < 0.001). The median time to discontinua-
tion for abatacept was 10.8 months. The percentage of
patients who remained on first-line anti-TNF therapy at 1
year was 51.4%, and 23.3% had continued with therapy at
2 years (note that continuous enrollment was required for
12 months). For the cohort of patients who used a subse-
quent anti-TNF therapy, 44.1% remained on therapy at 1
year and 17.4% remained on therapy at 2 years. When the
allowed gap for discontinuation was defined as 180 days,
median time to discontinuation increased by 0.4 to 4.9
months across all cohorts (Figure 2b).
Cox proportional hazards models for discontinuation
(more than 60 day gap or start of non-index biologic
agent) of anti-TNF agents are shown in Table 5. Com-
pared with first-line anti-TNF therapy, risk of disconti-
nuation was greater for subsequent-line therapy while
controlling for demographic and clinical characteristics
(combined anti-TNF cohorts hazard ratio [HR] 1.177; p
< 0.001). Among specific anti-TNF therapies, however,
only subsequent-line adalimumab was associated with a
significantly higher risk of discontinuation (HR 1.238; p
= 0.002). Risk of discontinuation remained significantly
greater for subsequent-line anti-TNF therapy when a
180-day gap was allowed (HR 1.280; p < 0.001), but
with this definition risk of discontinuation was signifi-
cantly greater for subsequent-line etanercept (HR 1.246;
p = 0.005) as well as for subsequent-line adalimumab
(HR 1.300; p < 0.001). Risk of subsequent-line infliximab
discontinuation was not significantly elevated versus
first-line using either the 60-day (HR 1.140; p = 0.214)
or 180-day (HR 1.201; p = 0.086) gap allowance.
Switching
Similar to discontinuation, the proportion of patients
with evidence of non-index therapy use during the fol-
low-up year, i.e., patients who switched medication, was
greater among subsequent-line anti-TNF users than
those in the first-line anti-TNF cohorts. For first-line
anti-TNF agents the percentage of patients who
switched to another therapy ranged from 12.0% (etaner-
cept) to 15.4% (adalimumab). For subsequent-line anti-
TNFs, the percentages ranged from 22.4% (infliximab)
to 38.2% (adalimumab). For the non-anti-TNF therapies,
23.4% switched from abatacept and 17.5% switched from
rituximab at some point during the follow-up year.
Discussion
Our descriptive analyses suggest that, on average, the
starting doses for biologic therapies for RA are in accor-
dance with the label recommendations. However, a sub-
stantial proportion of patients who received infliximab
had evidence of a dose escalation during follow-up. The
higher rates of dose escalation, discontinuation, switch-
ing, shorter dosing intervals, and shorter time to discon-
tinuation among patients previously exposed to anti-
TNF therapy are suggestive of reduced effectiveness or
poorer tolerance of subsequent anti-TNF agents after
failure of the initial anti-TNF therapy.
Table 5 Cox proportional hazards model of time-to-discontinuation (more than 60 day gap in days supply or start of
non-index biologic agent) of anti-TNF therapy
Overall
(N = 3984)
p value Etanercept
(N = 1851)
p value Adalimumab
(N = 1393)
p value Infliximab
(N = 740)
p value
Subsequent anti-TNF
(reference first anti-TNF)
1.177 < 0.001 1.121 0.133 1.238 0.002 1.140 0.214
Age (years) 0.990 < 0.001 0.989 < 0.001 0.987 < 0.001 1.004 0.325
Female (reference male) 0.884 0.006 0.827 0.005 0.870 0.063 1.066 0.529
Region (reference Northeast)
Midwest 0.954 0.545 0.874 0.218 1.005 0.973 1.198 0.386
South 1.016 0.829 0.886 0.222 1.066 0.618 1.366 0.113
West 0.930 0.370 0.791 0.043 1.095 0.520 1.068 0.758
Plan type (reference HMO)
PPO 0.985 0.821 1.039 0.697 0.875 0.232 1.128 0.493
POS 0.873 0.288 0.668 0.050 1.152 0.516 0.864 0.578
EPO 1.028 0.621 1.025 0.767 0.943 0.520 1.321 0.045
Indemnity 0.902 0.136 0.847 0.109 0.806 0.060 1.344 0.083
Baseline treatment
Methotrexate 0.836 < 0.001 0.871 0.013 0.832 0.003 0.801 0.014
NSAIDs 0.897 0.003 0.858 0.006 0.922 0.184 0.890 0.180
Corticosteroids 1.050 0.205 1.054 0.354 1.083 0.218 1.000 0.997
Baseline Charlson score 1.112 < 0.001 1.105 0.006 1.105 0.006 1.123 0.031
NSAID, non-steroidal anti-inflammatory drug; HMO, health maintenance organization; PPO, preferred provider organization; EPO, exclusive provider organization.
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results of previous studies showing reduced response
with subsequent anti-TNF use compared with the first
anti-TNF therapy as measured by changes in disease
activity or treatment continuation [21-24]. Finckh et al.
[25] have suggested that aspects of therapy utilization
including dose escalation and discontinuation may be
indicative of acquired resistance to therapy. Some pre-
vious studies have indicated that the response to subse-
quent anti-TNF therapy after failure of a first might still
be acceptable for some patients [23,24,26], but the pre-
sence of alternative therapies compels further compari-
sons of these treatments within the context of real-
world sequential administration practices. It has been
suggested that introducing therapy with a non-anti-TNF
mechanism of action may provide greater benefit than a
subsequent anti-TNF medication [27]. In clinical trials,
rituximab [28], abatacept [29,30] and tocilizumab [31] in
combination with methotrexate were shown to be
superior to methotrexate alone in patients who had an
inadequate response to an anti-TNF agent. However,
these studies did not compare the response achieved
with these alternative agents against that achieved with
a subsequent anti-TNF agent.
Finckh et al. compared a therapy providing an alterna-
tive mechanism of action, rituximab, with subsequent
anti-TNF therapy following an inadequate response to a
first anti-TNF and found a better clinical response with
rituximab [32,33]. They further examined the effective-
ness of these subsequent-line therapies in subgroups of
patients with differing reasons for switching from the
first anti-TNF agent, and found that the improvement
in disease activity was significantly better among
patients treated with rituximab versus a subsequent
anti-TNF agent when the reason for switching was
inadequate response [32]. When patients switched due
to other reasons (including adverse events), the
improvement in disease activity was similar between
patients who received rituximab and those who received
a subsequent anti-TNF agent [32]. In contrast, Blom et
al. found no association between reason for discontinua-
tion of the first anti-TNF agent and response to subse-
quent anti-TNF therapy [34].
A few studies have provided data regarding treatment
patterns with biologic RA therapies. Using the same
definition of dose escalation as we applied here, Gilbert
et al. investigated dose increases among patients first
treated with infliximab or etanercept [17]. Similar to our
findings, they reported that approximately 58% of first-
line infliximab users and 18% of patients receiving eta-
nercept had a dose increase within 1 year [17]. Using
different operational definitions, Nair et al. [35] found
that 45% of commercially-insured patients with evidence
of infliximab as a first-line biologic therapy had a dose
escalation (difference between first and final doses) in
the first year of therapy and, in a report based on a
Dutch registry of patients with RA who started a first
anti-TNF agent, Blom et al. [36] found dose increases in
36% of infliximab patients, 12% of adalimumab patients,
and 8% of etanercept patients. Although our estimates
for the comparable cohorts are based on a different defi-
nition of escalation, the overall pattern is the same; i.e.,
a high proportion of dose increases was observed among
patients on infliximab and a relatively low proportion
among those on etanercept. Although infliximab use
was associated with a high proportion of dose escala-
tions, we also observed that it had the longest continua-
tion, suggesting that patients on infliximab tended to
increase their dose rather than switch to another
medication.
Studies of persistence or continuation with biologic
therapy have produced varying results. Tang et al. [37]
reported that, among US patients using anti-TNF biolo-
gic therapy in combination with methotrexate, those on
infliximab had the longest duration of medication use
and those on adalimumab used it for the least amount
of time. Similarly, we found that infliximab use was
associated with the longest median time to discontinua-
t i o na n dl o w e s td i s c o n t i n u a t i o nr a t ea n dt h a ta d a l i m u -
mab was associated with the highest discontinuation
rate and shortest time to discontinuation among first-
line anti-TNF therapies. In contrast, data from a Danish
registry showed that risk of withdrawal among patients
using a first-line anti-TNF was greater for those on
infliximab than for those using another anti-TNF ther-
apy [38] and Italian registry data indicated that disconti-
nuation rates were also relatively higher for patients
who used infliximab [39]. Our patients showed a higher
rate of discontinuation from subsequent-line anti-TNF
therapy than those in a UK national registry [23]; in
that study, 73% of patients who switched to a second
anti-TNF remained on the new therapy through a mean
of 15 months of follow-up. These differences indicate
that a range of outcomes are possible for RA patients
receiving anti-TNF therapy and the variability could
reflect differences in preferences and practices across
different countries. Comparisons between our study and
these registry studies are also limited by the lack of clin-
ical data in our database (e.g., disease severity).
Our study provides an illustration of biologic therapy
utilization among patients with RA, but, like all claims-
based analyses, the results must be interpreted in the
context of several limitations. Claims are collected for
payment purposes, not research; thus they are limited in
the degree to which they represent a patient’s true med-
ical history. For example, claims-based evidence of a
prescription fill does not confirm that a patient used the
medication or used it appropriately. Medical claims
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Page 9 of 11indicating infusion administration are directly associated
with therapy use. However, a physician might not bill
for partial vials of medication (e.g., a 75 kg patient
receiving 225 mg of infliximab would require three 100
mg vials) and our operational definition of infusion
dose, which is based on the number of units billed for,
is likely to provide an overestimation of the number of
units administered. Patients in this study were not ran-
domly assigned to therapy and factors affecting the
selection of therapy or the choice to receive subsequent-
line biologic therapy could result in selection bias. Pre-
vious studies indicate that discontinuation or changes in
treatment are often attributable to inefficacy or adverse
events, and these reasons could influence the choice of,
or effectiveness of, subsequent therapy [21,23,32].
Although we are able to observe changes in treatment
with claims data, the reasons for adjusting or disconti-
nuing treatment and thus their possible effects on
patient outcomes are unknown. The impact of concomi-
tant medication use on study outcomes was not
assessed. Coding errors could affect our ability to detect
all relevant health care utilization. Finally, our study
sample represents working-aged managed care enrollees
and the results may not generalize to other patients.
Conclusions
Although the starting doses for biologic therapies for
RA are in accordance with the label recommendations,
a substantial proportion of patients who received inflixi-
mab had evidence of a dose escalation during follow-up
and subsequent-line anti-TNF therapy cohorts had
higher rates of discontinuation, dose escalation, and
shorter time to discontinuation than first-line anti-TNF
c o h o r t s .T h er o l eo fb i o l o g i ct h e r a p i e si nt h et r e a t m e n t
of RA continues to evolve, and further research is
needed to determine the optimal sequence for imple-
menting treatments with varied mechanisms of action,
based on patient characteristics, response and tolerance
to previous agents and comparative effectiveness of var-
ious biologic agents.
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